Developer docs
API playgroundTry for free, no card

Search company profiles

NeuralStem

Full company profile

uuid00069fx

Namestring
NeuralStem
Websiteurl
neuralstem.com
Company typeenum
Private
Founded yearint
1996
Descriptiontext

NeuralStem is a publicly traded clinical-stage biotherapeutics company (NASDAQ: SNCA) founded in 1996 and headquartered in Rockville, Maryland. The company is focused on applying neural stem cell research and technology to develop treatments for diseases of the central nervous system (CNS). It operates with a small team of 11-50 employees under founder, president and CEO I. Richard Garr.

NeuralStem's core technology platform centers on proprietary human neural stem cell lines and the methods to differentiate, manufacture, and deliver these cells as potential therapies for CNS indications. The company has historically pursued cell-based therapeutic candidates targeting conditions such as amyotrophic lateral sclerosis (ALS), spinal cord injury, and ischemic stroke, among other CNS disorders. Specific product candidates, IND status, and clinical pipeline details are not disclosed in the available input, but the platform implies a long, capital-intensive R&D cycle typical of cell therapy developers.

The business model is that of a pre-revenue clinical-stage biotech: NeuralStem funds its R&D through periodic equity and structured financings rather than product sales. Cumulative disclosed funding totals approximately $39.86M across seven rounds between 2010 and 2019, the largest being a $20M strategic investment from Tianjin Pharmaceutical Group International Holdings in December 2016. There is no disclosed product revenue, pricing, customer base, or partnership royalty stream; revenue mechanics will depend on future commercialization, licensing, or partnership milestones rather than current operating activity.

Short descriptiontext

NeuralStem is a publicly traded, clinical-stage biotherapeutics company that develops neural stem cell-based therapies for central nervous system diseases. Founded in 1996 in Rockville, Maryland, it operates with 11-50 employees under founder-CEO I. Richard Garr.

Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRockville, United States
HQ citystring
Rockville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
stem cell therapy, central nervous system, biotherapeutics research, neural regeneration, regenerative medicine
Industry3 codes
1Neural & Spinal Cord Regeneration
CodeHLAAAGAIPrimaryYes
2Neurology & CNS Specialty Pharmaceuticals
CodeHLAIACACPrimaryNo
3Neurology/CNS Gene Therapies
CodeHLAAACAHPrimaryNo
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Stem Cell Therapeutics
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

NeuralStem is a biotherapeutics company that applies stem cell research and proprietary neural stem cell technology to develop treatments for diseases of the central nervous system. Its core activity is the advancement of cell-based therapeutics targeting conditions such as neurodegenerative disorders and central nervous system injuries.

Differentiator
Functional benefit
Problem solved
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Market position
Competitive moat3 records

Each record includes

Type, Details

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NeuralStem

Stem Cell Therapeuticsneuralstem.com

NeuralStem is a publicly traded, clinical-stage biotherapeutics company that develops neural stem cell-based therapies for central nervous system diseases. Founded in 1996 in Rockville, Maryland, it operates with 11-50 employees under founder-CEO I. Richard Garr.

What NeuralStem does

NeuralStem is a publicly traded clinical-stage biotherapeutics company (NASDAQ: SNCA) founded in 1996 and headquartered in Rockville, Maryland. The company is focused on applying neural stem cell research and technology to develop treatments for diseases of the central nervous system (CNS). It operates with a small team of 11-50 employees under founder, president and CEO I. Richard Garr.

NeuralStem's core technology platform centers on proprietary human neural stem cell lines and the methods to differentiate, manufacture, and deliver these cells as potential therapies for CNS indications. The company has historically pursued cell-based therapeutic candidates targeting conditions such as amyotrophic lateral sclerosis (ALS), spinal cord injury, and ischemic stroke, among other CNS disorders. Specific product candidates, IND status, and clinical pipeline details are not disclosed in the available input, but the platform implies a long, capital-intensive R&D cycle typical of cell therapy developers.

The business model is that of a pre-revenue clinical-stage biotech: NeuralStem funds its R&D through periodic equity and structured financings rather than product sales. Cumulative disclosed funding totals approximately $39.86M across seven rounds between 2010 and 2019, the largest being a $20M strategic investment from Tianjin Pharmaceutical Group International Holdings in December 2016. There is no disclosed product revenue, pricing, customer base, or partnership royalty stream; revenue mechanics will depend on future commercialization, licensing, or partnership milestones rather than current operating activity.

NeuralStem firmographics

Firmographics
Name
NeuralStem
Website
https://neuralstem.com
Company type
Private
Founded year
1996
Headcount range
11–50 employees
Short description
NeuralStem is a publicly traded, clinical-stage biotherapeutics company that develops neural stem cell-based therapies for central nervous system diseases. Founded in 1996 in Rockville, Maryland, it operates with 11-50 employees under founder-CEO I. Richard Garr.
Ownership category
akta.pro rank

NeuralStem industry classification

Industry
Product category
Stem Cell Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro primary industry
Neural & Spinal Cord Regeneration (HLAAAGAI)
akta.pro secondary industries
Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Neurology/CNS Gene Therapies (HLAAACAH)

Keywords

  • Stem cell therapy
  • Central nervous system
  • Biotherapeutics research
  • Neural regeneration
  • Regenerative medicine

Where NeuralStem is headquartered

Location

Headquarters

HQ city
Rockville
HQ country
United States
HQ region
North America

Markets served

NeuralStem business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

NeuralStem product offering

Product offering

Core offering

NeuralStem is a biotherapeutics company that applies stem cell research and proprietary neural stem cell technology to develop treatments for diseases of the central nervous system. Its core activity is the advancement of cell-based therapeutics targeting conditions such as neurodegenerative disorders and central nervous system injuries.

Differentiator

Problem solved

Functional benefit

Companies that use NeuralStem

Customer profile

Ideal customer profiles1 record

NeuralStem technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

NeuralStem partnerships and signals

Strategic signal

Recent moves6 records

Expansion highlights2 records

NeuralStem competitors and assessment

Company assessment

Market position

Competitive moat3 records

Key highlights5 records

Customer concentration

NeuralStem social profiles

Digital presence

NeuralStem financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NeuralStem leadership team

Management profile

Number of profiles

Profiles1 record

NeuralStem funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NeuralStem M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeuralStem

What does NeuralStem do?

NeuralStem is a biotherapeutics company that applies stem cell research and proprietary neural stem cell technology to develop treatments for diseases of the central nervous system. Its core activity is the advancement of cell-based therapeutics targeting conditions such as neurodegenerative disorders and central nervous system injuries.

When was NeuralStem founded?

NeuralStem was founded in 1996. It employs 11 to 50 people.

Where is NeuralStem based?

NeuralStem is headquartered in Rockville, United States, in the North America region.

Does NeuralStem have an API?

No public API is recorded for NeuralStem.

What industry is NeuralStem in?

NeuralStem's product category is Stem Cell Therapeutics. Its primary akta.pro industry code is HLAAAGAI, Neural & Spinal Cord Regeneration, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireNeuralstem Becomes Seneca BiopharmaNeuralstem, Inc. (NASDAQ:CUR) announced a name change to Seneca Biopharma, Inc. on October 28, 2019, with shares expected to begin trading under the new symbol SNCA on the NASDAQ Capital Market around November 1, 2019. The rebranding reflects a strategic pivot from neurological disorder research toward acquiring new assets, developing a broader biopharmaceutical pipeline, and commercializing products to create stakeholder value. Executive chairman Dr. Ken Carter stated the change represents a new organizational philosophy aimed at addressing unmet medical needs.PR NewswireNeuralstem Announces Last Subject Enrolled in Phase 2 Clinical Trial Evaluating Human Neural Stem Cells in Chronic Stroke PatientsNeuralstem, Inc. announced the completion of subject enrollment for its Phase 2 clinical trial evaluating NSI-566, a human neural stem cell therapy, in chronic stroke patients. The double-blind study, conducted at BaYi Brain Hospital in Beijing, enrolled 22 subjects to assess efficacy and safety over a 12-month period following treatment. Results from this trial are expected in the second half of 2020.PR NewswireNeuralstem Announces Nasdaq Hearings Panel Grants Request For Continued ListingNeuralstem, Inc. announced on August 6, 2019, that the Nasdaq Hearings Panel granted the company's request for continued listing on the Nasdaq Stock Market, after finding that Neuralstem demonstrated compliance with bid price requirements and addressed questions regarding its stockholders' equity position. The Panel determined the matter closed, allowing the company's stock to remain listed. The company is a clinical-stage biopharmaceutical developing stem cell therapies and small molecule treatments for nervous system diseases and depression.PR NewswireNeuralstem Closes $7.5 Million Underwritten Public OfferingNeuralstem, Inc., a clinical-stage biopharmaceutical company listed on Nasdaq, has closed an underwritten public offering of 2,777,777 units at $2.70 per unit, generating gross proceeds of approximately $7.5 million before deducting discounts, commissions, and estimated offering expenses. Each unit comprises one share of common stock (or common stock equivalent), one short-term warrant exercisable at $2.70 per share through December 31, 2020, and one long-term warrant exercisable at $2.70 per share for five years from issuance. H.C. Wainwright & Co. acted as the sole book-running manager for the offering, which was conducted pursuant to a registration statement declared effective by the SEC on July 25, 2019.PR NewswireNeuralstem Announces Pricing of $7.5 Million Underwritten Public OfferingNeuralstem, Inc., a clinical-stage biopharmaceutical company focused on nervous system disease treatments, announced the pricing of an underwritten public offering of 2,777,777 units at $2.70 per unit for gross proceeds of approximately $7.5 million. H.C. Wainwright & Co. is acting as sole book-running manager for the offering, which is expected to close on or about July 30, 2019. The company intends to use the approximately $6.6 million in net proceeds for further development of its stem cell and small molecule assets, advancement of its acquisition and in-licensing strategy, and general corporate purposes.PR NewswireNeuralstem Appoints Mary Ann Gray, Ph.D., to Board of DirectorsNeuralstem, Inc., a biopharmaceutical company focused on nervous system therapies, appointed Mary Ann Gray, Ph.D. to its Board of Directors on July 18, 2019. Dr. Gray brings over 15 years of experience serving on public company boards, with expertise spanning pharmacology, drug development, and finance, having most recently served on the boards of Senomyx and Juniper Pharmaceuticals, both recently acquired.PR NewswireNeuralstem Announces a 1-for-20 Reverse Stock SplitNeuralstem, Inc. announced a 1-for-20 reverse stock split effective July 17, 2019, to regain compliance with NASDAQ's $1.00 minimum bid price listing requirement. This corporate action reduces the company's outstanding common stock from approximately 21.3 million shares to roughly 1.07 million shares while maintaining existing trading symbols.PR NewswireNeuralstem Announces Publication of Results from Phase 1 Clinical Trial Evaluating Human Neural Stem Cells in Chronic Stroke PatientsNeuralstem, Inc. announced publication of Phase 1 clinical trial results in Stem Cells Translational Medicine evaluating its NSI-566 stem cell therapy for motor deficits in chronic ischemic stroke patients. The trial, conducted at BaYi Brain Hospital in Beijing, China with nine subjects, showed the treatment was well-tolerated at all doses with subjects demonstrating stable motor score improvements over 24 months of monitoring. The positive Phase 1 data has already led to the initiation of a placebo-controlled trial at the same site in September 2018.PR NewswireNeuralstem Appoints David J. Mazzo, Ph.D., to Board of DirectorsNeuralstem, Inc. announced the appointment of David J. Mazzo, Ph.D. to its Board of Directors, effective June 12, 2019, replacing retiring director Stanley Westreich. Dr. Mazzo brings over 30 years of pharmaceutical and biotech industry experience and currently serves as Chief Executive Officer of Caladrius Biosciences. The company stated he will provide significant value as Neuralstem continues developing its neural stem cell and small molecule technologies for nervous system diseases.PR NewswireNeuralstem to Expand Pipeline as Part of Aggressive Growth EffortNeuralstem, Inc. (NASDAQ: CUR), a clinical-stage biopharmaceutical company based in Germantown, Maryland, announced a strategic initiative to expand its therapeutic product pipeline by evaluating new technologies and identifying preclinical and clinical stage assets. The expansion follows the appointment of Kenneth C. Carter, Ph.D. as Executive Chairman, who brings experience from prior leadership roles at Avalon Pharmaceuticals and Neximmune. The company currently has two technologies in Phase II clinical trials: MSI-189, a small molecule for major depressive disorder, and NSI-566, a stem cell therapy for ALS.